Imunocare completed a Series A financing of 250 million yuan to accelerate the development of a globally leading fully human antibody discovery platform.

[Shanghai, May 13, 2026] Shanghai Yiminokang Biotechnology Co., Ltd. (hereinafter referred to as "Yiminokang") announced the completion of a Series A financing of 250 million yuan. This round of financing was led by OrbiMed, followed by Gaomai Yuanhang. The old shareholders, Xicheng Jinrui and Taiyu Investment, made large - scale over - subscribed additional investments. Light Capital served as the exclusive financial advisor. The funds from this round of financing will be mainly used for accelerating the continuous R & D of the gene - edited animal platform, the commercialization of the fully human antibody rabbit platform, the establishment of the AI antibody drug screening platform, the development of framework antibodies for complex targets, and the company's daily operations and team expansion.

Yiminokang was founded in 2020 and focuses on building the next - generation antibody discovery platform with gene - editing technology. The independently developed  MASIRT® (Massive - fragment Across Species In situ Replacement Technology) of the company has achieved three core breakthroughs: By adopting the strategy of linear artificial chromosome loading, it has significantly improved the gene fragment loading capacity; A single operation can complete the in - situ replacement of Mb - level DNA fragments, significantly reducing the number of edits; The MASIRT technology is not restricted by species and has achieved large - fragment replacement among multiple species. In addition to the fully human mouse platform, the company has further completed strategic positioning with the globally original ImmuAlpaca® alpaca - mouse platform, fully human rabbit and rabbit - derived single - chain antibody rabbit platform, filling the market gap in the field of multi - species, high - diversity model animals, and has completed the global patent layout covering major markets such as the Chinese mainland, Europe, the United States, and Japan. The synergy of the three technological advantages has significantly compressed the construction cycle of the fully human antibody animal platform, significantly improved the efficiency and success rate of antibody screening, and provided a more efficient source innovation tool for antibody drug R & D. The company is simultaneously promoting the construction of the MabAI® AI antibody discovery platform. Relying on the multi - species immune data with an annual output of over 100 million high - quality sequences, it constructs an AI antibody generation and characterization model, significantly improving the screening efficiency and druggability level, and creating an innovative system of "fully human model animals + AI empowerment".

Yiminokang has established a cooperation system covering many well - known pharmaceutical companies at home and abroad, including the top ten multinational pharmaceutical companies in the world. The industrial value of its technology platform has been fully verified by international leading partners. At the same time, the company is actively expanding the diversified application scenarios of platform technology with many biotechnology companies.

Dr. Zhang Jiwei, the founder of Yiminokang, said: "We sincerely thank the new and old shareholders and partners for their trust and strong support! This 250 - million - yuan Series A financing is an important milestone in Yiminokang's development and a key driving force for the company's pattern transformation and strategic leap. In the future, we will rely on our independent core multi - species, multi - source antibody discovery technology to accelerate platform construction and pipeline layout, support the source innovation and development of China's biomedicine, expand the global industrial cooperation ecosystem, build an internationally leading antibody discovery platform, and provide professional and efficient R & D solutions; We will achieve leap - forward growth driven by both capital and technology to bring more breakthrough therapies to global patients."

Fu Shan, the managing partner of OrbiMed, said: "The new - generation fully human model animal platform, combined with AI intelligent R & D capabilities, will become a powerful engine for the development of innovative biopharmaceuticals. Yiminokang has not only fully verified the advantages of its platform in antibody screening for several complex targets and won high recognition from MNCs; At the same time, relying on the rich data assets accumulated from diverse model animals, it is expected to further deeply integrate AI algorithms to build an intelligent antibody discovery system, empowering the entire process of antibody sequence generation, characterization, and druggability prediction, significantly shortening the R & D cycle and improving the success rate of candidate drugs. OrbiMed is optimistic about the MASIRT technology with obvious differential advantages of the company and the multi - species, high - quality fully human model animal platform it has built, and believes that this platform can greatly empower the development of global innovative antibody drugs. We look forward to closely cooperating with Yiminokang and its team, making full use of OrbiMed's global ecological resources, accelerating the internationalization of platform cooperation, and supporting the development and implementation of its innovative pipelines."

Fu Dongping, the partner of Gaomai United Family Office, said: "Gaomai is optimistic about the independently developed MASIRT® technology of Yiminokang, which can achieve in - situ replacement of ultra - large - fragment cross - species genes, break through the traditional problem of humanizing rabbit monoclonal antibodies, aiming to improve the global R & D level of therapeutic antibodies and support the innovation and breakthrough in China's biomedicine field. Gaomai supports innovative technology companies like Yiminokang to help family capital achieve high - quality inheritance while giving back to society."
 

Chen Leiwen, the managing partner of Xicheng Jinrui, said: "Yiminokang has a globally leading gene - editing technology platform and efficient new drug molecule development capabilities. As the earliest investment institution of the company, Xicheng Jinrui has continuously increased its investment in 2021, 2023, and 2025, and introduced business partners for the company. We have witnessed the company's progress and growth and hope that Yiminokang will develop more clinically advantageous antibody drugs for global patients."

Dr. Ji Tianrong, the founder & general manager of Taiyu Investment, said: "Yiminokang is a 'pioneer' in the in - situ replacement technology of large - fragment genes in China. Relying on the artificial chromosome vector with independent intellectual property rights, it has globally leading fully human antibody mice, fully human single - chain antibody mice, fully human co - light chain antibody mice, and alpaca antibody mice, all of which have been commercialized and well - received by the market. It has also signed strategic cooperation agreements with many MNCs and well - known domestic pharmaceutical companies. In addition, we hope that Yiminokang's globally scarce fully human antibody rabbit platform will be commercialized soon to support the improvement of new drug R & D efficiency."

Hong Lei, the head of the medical group and managing director of Light Capital, said: "We are very honored to accompany Yiminokang to complete this round of financing. Since our first contact, we have witnessed the whole process of the company's platform technology being continuously recognized by the world's top pharmaceutical companies and first - tier funds. In the current situation where antibody drug R & D is increasingly returning to source innovation, Yiminokang's technological barriers and platform capabilities are particularly scarce. We look forward to continuing to support the company, enabling this Chinese - originated innovation platform to serve more pharmaceutical companies globally and helping Chinese wisdom go global."